News

FDA has granted designation for idebenone for the treatment of Duchenne Muscular Dystrophy.

Scientists at UC Berkeley have developed a novel way to engineer the growth and expansion of energy-burning “good” fat, and then found that this fat helped reduce weight gain and lower blood glucose levels in mice.

Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.

Valeant and Sprout Pharmaceuticals have announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.

Scientists found that when two protein structures in the brain join up, they act as an amplifier for a slight increase in calcium concentration, triggering a gunshot-like release of neurotransmitters from one neuron to another.

Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.

A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.

Novartis has announced that the European Commission has approved Odomzo® 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to curative surgery or radiation therapy.

UCSF-designed tests pinpoint rare infectious agents far more rapidly than conventional methods.

Hundreds of highly skilled jobs are expected to be created and safeguarded in Nottingham with the news that work can now start on a new £30m life science building adjacent to the current BioCity site on Pennyfoot Street.